New research sheds light on the real number of people living with rare diseases globally and calls for the prioritization of these conditions.
Fri Nov 01, 2019 16:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna announced it approved the purchase a total of 209,500 shares of common stock to be distributed among 13 new employees.
02:06
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its third quarter 2019 financial results on Thursday, November 7, 2019 at 7:00 a.m. ET. Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-866-966-1396; Israel 1-809-203-624 or International +4
00:00
Publication date: Available online 31 October 2019Source: Contemporary Clinical TrialsAuthor(s): Peter F. ThallAbstractTwo illustrative applications are presented of Bayesian clinical trial designs that make adaptive subgroup-specific decisions based on elicited utilities of patient outcomes to quantify risk-benefit trade-offs. The first design is for a randomized trial to evaluate effects of nutritional prehabilitation on post-operative morbidity in esophageal cancer patients undergoing surgery....
Fri Nov 01, 2019 19:03
LACHEN, Svizzera--(BUSINESS WIRE)--Octapharma ha annunciato la pubblicazione di nuovi dati che dimostrano che il concentrato di fibrinogeno, fibryga®, rappresenta un'alternativa efficace al crioprecipitato per i pazienti con perdite ematiche severe nel corso della chirurgia cardiaca. I dati sono stati recentemente pubblicati sul Journal of the American Medical Association (JAMA).1 I sanguinamenti eccessivi rappresentano un problema importante nel corso degli interventi chirurgici: livelli ecces
Fri Nov 01, 2019 17:00
DUBLIN--(BUSINESS WIRE)--The "OTC/DTC Infectious Disease Diagnostics - Strategies and Trends, Forecasts By Application, By Channel, By Country - With Market Analysis, Executive Guides and Customization - 2020 to 2024" report has been added to ResearchAndMarkets.com's offering. This report explores the DTC outlook for different syndromes. Find out where the action is and the learn about the players. The report has hundreds of pages of information including a complete list of Current 2019 United
Fri Nov 01, 2019 16:42
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova honors National Epilepsy Awareness Month in the United States this November and is working to bring more awareness to epilepsy.
Fri Nov 01, 2019 15:00
METUCHEN, N.J.--(BUSINESS WIRE)-- #adaptivedatamanagement--MaxisIT today announced that it has GONE LIVE with MaxisIT’s Integrated Clinical Development Platform together with Tobacco Harm Reduction pioneer, Philip Morris International (PMI). PMI has awarded MaxisIT a multi-year SaaS agreement to use MaxisIT’s Clinical Data Repository, Clinical data management Hub, Statistical computing Environment and Analytics solutions for their global clinical assessment program. This pioneering agreement for...
Fri Nov 01, 2019 14:30
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today provided an update on the temporary unavailability of NATESTO® in Canada and South Korea, following the previous announcement of the voluntary replacement of certain NATESTO® lots released on the Canadian and South Korean markets. Acerus made minor modifications to the manufacturing process that appear to have resolved the previously identified issues and has produced a batch of NATESTO® (the “Revised Batc
Fri Nov 01, 2019 14:30
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Checkmate Pharmaceuticals Inc., today announced two oral presentations at The 34th Annual Meeting of The Society for Immunotherapy of Cancer (SITC).
Fri Nov 01, 2019 14:01
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced that its lead investigational medicine, COR388, will be the subject of an oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2019. The company will also host a lunch briefing on the pr
Fri Nov 01, 2019 14:00
The study is the first in the strategic oncology partnership announced between Daiichi Sankyo and Sarah Cannon, designed to expedite and optimize global clinical development of Daiichi Sankyo’s The post Daiichi Sankyo initiates clinical trial of DS-7300 in collaboration with Sarah Cannon Research Institute appeared first on Pharmaceutical Business review.
Fri Nov 01, 2019 13:25
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2019. “The FORWARD I analyses presented at ESMO have provided us with valuable insights into the patients who benefit most from mirvetuximab,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer. “We have si
Fri Nov 01, 2019 12:30
This agreement covers four products in rare metabolic and neurological disorders and each product will utilise Catalent’s Zydis® oral disintegrating tablet (ODT) and Zydis Ultra® technologies. Zydis technology The post Cycle Pharmaceuticals and Catalent partner to develop treatments for rare diseases using Zydis ODT technology appeared first on Pharmaceutical Business review.
Fri Nov 01, 2019 12:25
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου